乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ACR

<乌鸦传媒>Safer Alternative to Cyclophosphamide at Hand for ILD?

Drug targeting B cells as effective as broad-spectrum immunosuppressant in lung disease

<乌鸦传媒>Novel BTK Inhibitor Looks Good for Sjogren's Syndrome

Phase II data show good efficacy by objective measures, even with strong placebo effect

<乌鸦传媒>ANCA-Associated Vasculitis: Novel Biologic Shows Promise for Replacing Steroids

Small trial demonstrates big cut in steroid-linked adverse effects

<乌鸦传媒>Twelve-Month Data Back Pegloticase-Methotrexate Gout Combo

More support for add-on methotrexate to maintain protein drug's efficacy

<乌鸦传媒>Want a Few Weeks of Knee Pain Relief? Try This

Local nerve block proves mettle in randomized trial, though benefit didn't last long

<乌鸦传媒>For Systemic JIA, Start Biologics Early

Observational study shows excellent efficacy in systemic pediatric arthritis

<乌鸦传媒>Secukinumab: An Up-and-Coming Option in Giant Cell Arteritis?

Phase II trial found sustained remission with steroid-sparing effects

<乌鸦传媒>Voclosporin Benefits in Nephritis Persist at 30 Months

No new safety signals seen in long-term extension for lupus nephritis

<乌鸦传媒>Vitamin D and Disease Prevention: Worth Another Look?

Incidence of autoimmune disease decreased by 25-30% with dietary supplements

<乌鸦传媒>Guselkumab Response Durable in Psoriatic Arthritis

Skin and joint improvements persisted through 2 years of follow-up

<乌鸦传媒>Early Biologics Better in Juvenile Idiopathic Arthritis

After 2 years, more patients on combo biologic/DMARD regimen had inactive disease

<乌鸦传媒>Brepocitinib Shows Promise in Phase II Trial for PsA

Oral tyrosine kinase 2/JAK-1 inhibitor improved both joint and skin manifestations

<乌鸦传媒>Targeting IL-23 Succeeds in Psoriatic Arthritis

Patients had active, longstanding disease and inadequate responses to other agents

<乌鸦传媒>Can Abatacept Reverse Early Rheumatoid Arthritis?

At-risk patients showed improvements in inflammation -- and also delays in disease onset

<乌鸦传媒>TYK2 Inhibition Promising in Psoriatic Arthritis

Phase II study found significant benefits for two doses of novel agent

<乌鸦传媒>High B-Cell Depletion Succeeds in Lupus Nephritis

Obinutuzumab was more effective at depleting B cells than rituximab

<乌鸦传媒>COVID Complications Common with Rheumatic Disease

Adverse outcomes included acute kidney injury and congestive heart failure

<乌鸦传媒>Rinvoq for RA: Benefits Persist Beyond 1 Year

Manufacturer's extension study shows no loss of clinical response

<乌鸦传媒>ACR: Treat-to-Target Endorsed for Gout

Differs from ACP guideline for primary care: "they're wrong"

<乌鸦传媒>ACR: Draft OA Guidelines Stress Non-Drug Tx, Leave Opioid Door Open

But group comes down hard on stem cells, PRP, electrical therapy; downgrades hyaluronic acid shots

<乌鸦传媒>Rheumatoid Arthritis Is No Bar to Cancer Immunotherapy

Small study finds flares common with checkpoint inhibitors, but few patients stopped treatment because of them

<乌鸦传媒>Reassurance on Live-Virus Shingles Vax With Anti-TNFs

Randomized trial indicates fears of infection unfounded

<乌鸦传媒>BTK Inhibitor Passes Phase II Test in RA

Novel mechanism for a rheumatoid arthritis drug

<乌鸦传媒>Abuse in Many Fibromyalgia Patients' Past

And tied to more severe symptoms

<乌鸦传媒>ACR: Can Tanezumab Be Revived for OA?

Low incidence of rapidly progressive OA seen with lower doses

<乌鸦传媒>In Psoriatic Arthritis, Doubling Down on IL-17

Bimekizumab targets both IL-17A and F; "astonishing" results in psoriatic arthritis

<乌鸦传媒>Treat-to-Target Strategy Cuts Mortality in Gout Patients

Study sets serum urate therapeutic level

<乌鸦传媒>ACR: IL-12/23 Blocker Offers Long-Term Benefits in SLE

Responses were sustained out to 1 year with ustekinumab

<乌鸦传媒>Childhood Trauma: Risk Factor for Lupus in Adulthood?

Nurses Health Study data show a link

<乌鸦传媒>RA Guideline Adherence Spotty, Study Finds

Treat-to-target recommendation not followed for half of patients

<乌鸦传媒>Recurrent Post-Transplant Lupus Nephritis Declining

Single-center study credits improvements in immunosuppression

<乌鸦传媒>Is JAK Inhibition the Next Big Thing in PsA?

Proof-of-concept study suggests a potential role for oral filgotinib

<乌鸦传媒>New JAK1 Agent Beats Humira in Rheumatoid Arthritis

Thrombotic events balanced between upadacitinib, adalimumab, and placebo

<乌鸦传媒>Can Imaging Replace Biopsy for GCA Diagnosis?

Ultrasound, PET/CT may offer advantages

<乌鸦传媒>Selective IL-23 Inhibitor Shines in Mid-Stage PsA Trial

Risankizumab broadly effective against joint and skin symptoms

<乌鸦传媒>PsA Structural Damage Inhibited with Secukinumab

Loading dose appears to improve outcomes, researchers say

<乌鸦传媒>Novel Drug Promising for IgG4-Related Disease

8 of 15 patients achieved remission in phase II study

<乌鸦传媒>Prospects Good for Ustekinumab Gaining SLE Indication

Positive phase II data reported in ACR late-breaker

<乌鸦传媒>ACR Poster Roundup: Novel OA Tx; Cancer and RA Biologics

Selections from late-breaker poster presentations at rheumatology meeting

<乌鸦传媒>Mixed Results in Studies of Biosimilar-Originator Switching

Is there a nocebo effect in changing between drugs supposed to be equal?

1